Increasing rates of ESBL-producing Escherichia coli and Klebsiella pneumoniae in Canadian Hospitals: 17 years of the CANWARD study, 2007-23
- PMID: 40873024
- DOI: 10.1093/jac/dkaf220
Increasing rates of ESBL-producing Escherichia coli and Klebsiella pneumoniae in Canadian Hospitals: 17 years of the CANWARD study, 2007-23
Abstract
Objectives: ESBL-producing Escherichia coli and Klebsiella pneumoniae are major causes of infections, including urinary tract, abdominal, nosocomial pneumonia, diabetic foot and bloodstream infections. This study examines trends in their prevalence, genotypes and antibiotic susceptibility and identifies at-risk populations.
Methods: Between 2007 and 2023, bacterial isolates were collected from sentinel laboratories (CANWARD study). Identification, antimicrobial susceptibility testing and WGS were performed. Trends in incidence, resistance patterns, beta-lactamase genotypes and demographic associations were analysed using multifactorial regression and trend analysis.
Results: Among 11 931 E. coli and 3973 K. pneumoniae isolates, 8.4% and 5.6%, respectively, were ESBL-producers, with prevalence increasing from 2007-08 to 2021-23 (E. coli: 3.6% to 11.8%; K. pneumoniae: 2.2% to 8.0%; P < 0.001). Susceptibility among ESBL E. coli declined for amoxicillin-clavulanate (78.7% to 28.6%) but increased for gentamicin (43.5% to 70.3%) (P < 0.001). MDR among ESBL-positive E. coli declined (82.4% to 63.4%; P < 0.001) but remained stable among ESBL-positive K. pneumoniae. ESBL E. coli was associated with inpatients, respiratory specimens and males, while K. pneumoniae was linked to inpatient status and regional variations. Genotypic analysis showed increasing blaCTX-M-15 in K. pneumoniae and blaCTX-M-27 in E. coli. blaOXA-1 and blaTEM-1 were associated with MDR and first-generation β-lactam/β-lactamase inhibitor resistance.
Conclusion: ESBL E. coli and K. pneumoniae have increased in prevalence, with evolving resistance patterns. While MDR in E. coli has declined, resistance to key antimicrobials, including sulphonamides, fluoroquinolones and first-generation β-lactam/β-lactamase inhibitors remains high. Resistance rates varied significantly by region of Canada and by inpatient status, sex and specimen type.
© The Author(s) 2025. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.
Similar articles
-
Epidemiology, antibiotic resistance, and molecular detection of blaOXA and blaCTX-M Genes in ESBL-Producing Escherichia coli from urinary tract infections in Jordanian hospitals.BMC Microbiol. 2025 Aug 28;25(1):557. doi: 10.1186/s12866-025-04156-4. BMC Microbiol. 2025. PMID: 40877762 Free PMC article.
-
Molecular epidemiology of extended-spectrum β-lactamase-, AmpC β-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11.J Antimicrob Chemother. 2013 May;68 Suppl 1:i57-65. doi: 10.1093/jac/dkt027. J Antimicrob Chemother. 2013. PMID: 23587779
-
Whole-Genome Sequencing and Bioinformatics Analysis of ESBL- producing Klebsiella pneumoniae in a Ghanaian teaching hospital.BMC Microbiol. 2025 Jul 2;25(1):401. doi: 10.1186/s12866-025-04101-5. BMC Microbiol. 2025. PMID: 40604438 Free PMC article.
-
Prevalence of carbapenemase genes in Klebsiella pneumoniae and Escherichia coli isolated from intensive care unit patients in Iran: a systematic review (2014-2025).Mol Biol Rep. 2025 Jul 1;52(1):660. doi: 10.1007/s11033-025-10774-y. Mol Biol Rep. 2025. PMID: 40590995 Review.
-
Extended-spectrum beta-lactam-resistant Klebsiella pneumoniae in sub-Saharan Africa: a systematic review and meta-analysis from a One Health perspective.BMC Infect Dis. 2025 Jul 1;25(1):843. doi: 10.1186/s12879-025-11276-9. BMC Infect Dis. 2025. PMID: 40597808 Free PMC article.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical